UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/748,947	12/29/2003	Daniel L. Cox	ACS 66148 (1675XDC)	7894
24201 75 FULWIDER PA	90 01/18/200 FTON LLP	EXAMINER		
HOWARD HUGHES CENTER			PELLEGRINO, BRIAN E	
6060 CENTER DRIVE, TENTH FLOOR LOS ANGELES, CA 90045		OR ·	ART UNIT	PAPER NUMBER
			3738	
GUODED STATITORY	DENIOD OF DEGROVICE	MAN DATE	T DELIVER	VMODE
SHORTENED STATUTORY I	PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE	
3 MONT	THS	01/18/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

	Application No.	Applicant(s)			
	10/748,947	COX ET AL.			
Office Action Summary	Examiner	Art Unit			
	Brian E. Pellegrino	3738			
The MAILING DATE of this communication ap Period for Reply	ppears on the cover sheet with the c	correspondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).					
Status					
1)⊠ Responsive to communication(s) filed on 12/	<u>29/03</u> .				
2a) This action is FINAL . 2b) ⊠ Th	is action is non-final.				
3) Since this application is in condition for allow	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is				
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
4)⊠ Claim(s) <u>17-28</u> is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6)⊠ Claim(s) <u>17-28</u> is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/or election requirement.					
Application Papers					
9) The specification is objected to by the Examiner.					
10) The drawing(s) filed on is/are: a) ac					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).					
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:					
1. Certified copies of the priority documents have been received.2. Certified copies of the priority documents have been received in Application No					
 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage 					
application from the International Bureau (PCT Rule 17.2(a)).					
* See the attached detailed Office action for a list of the certified copies not received.					
Attachment(s)					
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)					
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date Notice of Informal Patent Application					
Paper No(s)/Mail Date 6) Other:					

DETAILED ACTION

Claim Objections

Applicant is advised that should claim18 be found allowable, claim 24 will be objected to under 37 CFR 1.75 as being a substantial duplicate thereof. When two claims in an application are duplicates or else are so close in content that they both cover the same thing, despite a slight difference in wording, it is proper after allowing one claim to object to the other as being a substantial duplicate of the allowed claim. See MPEP § 706.03(k).

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 17-19,23,24,25,28 are rejected under 35 U.S.C. 103(a) as being unpatentable over Klemm (5458615) in view of DeMello et al. (5429597). Fig. 4 shows a cross-section of the delivery system having a sheath 10 and an inner tubular member 13 with annular space 11 formed between the outer and inner members. Fig. 12 shows a housing assembly 51 with a base and a slidable handle 53 thereon. Fig. 1 shows the system with a guide wire lumen 22 extending from the proximal to distal end of the inner tubular member. It can be construed that the guidewire lumen has a fluid receiving

Page 3

opening 23 and into the annular space and means 17 for evacuating air from the catheter through the sheath. Figs. 10-12 show a fitting 56 connected to the housing assembly for attachment to the inner tubular member 12. Fig. 2 of Klemm shows a tip component 58 having a tapered shape and a distal opening 61. Klemm also discloses to place radiopaque material at the distal end for visibility purposes during insertion, col. 9, lines 26-35. However, Klemm does not disclose the tip component is made of a polymeric material compounded with a radiopaque substance. DeMello et al. teach that tips for catheters can be made of polymeric material, such as a poly-ether-block amide compounded with a radiopaque substance, col. 5, lines 6-21. It would have been obvious to one of ordinary skill in the art to use a radiopaque substance in a polymer as taught by DeMello et al. with the catheter system of Klemm et al. in order to enhance the visibility of the end of the catheter at the tip for the surgeon to use the system more precisely.

Claims 20,26,27 are rejected under 35 U.S.C. 103(a) as being unpatentable over Klemm et al. '615 in view of DeMello et al. '597 and further in view of Houser (5876369). Klemm as modified by DeMello is explained supra. However, Klemm in view of DeMello do not disclose the use of BaSO₄ in the PEBAX material of the catheter tip. Houser teaches that BaSO₄ is incorporated into polymers to provide radiopacity for enhancing fluoroscopic observations when using the system, col. 6, lines 11-19. It would have been obvious to one of ordinary skill in the art to incorporate the specific radiopaque material BaSO₄ in a polymer as taught by Houser using the catheter system of Klemm as modified by DeMello such that the tip has enhanced visibility for insertion purposes.

Page 4

Double Patenting

A rejection based on double patenting of the "same invention" type finds its support in the language of 35 U.S.C. 101 which states that "whoever invents or discovers any new and useful process ... may obtain a patent therefor ..." (Emphasis added). Thus, the term "same invention," in this context, means an invention drawn to identical subject matter. See *Miller v. Eagle Mfg. Co.*, 151 U.S. 186 (1894); *In re Ockert*, 245 F.2d 467, 114 USPQ 330 (CCPA 1957); and *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970).

A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the conflicting claims so they are no longer coextensive in scope. The filing of a terminal disclaimer <u>cannot</u> overcome a double patenting rejection based upon 35 U.S.C. 101.

Claims 21,22 are rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 1,6 of prior U.S. Patent No. 6695862. This is a double patenting rejection.

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Art Unit: 3738

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Page 5

Claims 17-24,28 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-6,13 of U.S. Patent No. 6695862. Although the conflicting claims are not identical, they are not patentably distinct from each other because this application's claims are merely broader than the patented claims of 6695862. See *In re Goodman*.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brian E. Pellegrino whose telephone number is 571-272-4756. The examiner can normally be reached on Monday-Friday from 7:30 to 4pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Corrine McDermott, can be reached on 571-272-4754. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

Application/Control Number: 10/748,947

Art Unit: 3738

you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free).

TC 3700, AU 3738

Page 6

BRIAN E. PELLEGRINO PRIMARY EXAMINER Buan E Mellegrin